CDIB Capital
VC Fund
Hong Kong, Hong Kong
CDIB Capital is a VC fund in Hong Kong focused on Health Care and Biotechnology. CDIB Capital International Corporation (“CDIB Capital”) operates as the overseas investment arm of China Development Financial (“CDF” or
- Total investments:
- 49
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $405M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries CDIB Capital invests in
Stages CDIB Capital invests in
Countries CDIB Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Series A
- $1.5M–$18M
- Series B
- $6M–$100M
- Series C
- $4.3M–$40M
Investment Focus
Industry
- Health Care 11 (22%)
- Biotechnology 10 (20%)
- Artificial Intelligence 7 (14%)
- Information Technology 6 (12%)
- Medical 5 (10%)
Stage
- Series B 16 (33%)
- Series A 10 (20%)
- Series C 7 (14%)
- Funding Round 4 (8%)
- Seed 2 (4%)
Country
- China 12 (24%)
- Taiwan 11 (22%)
- United States 11 (22%)
- Singapore 2 (4%)
- Japan 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alex Ying
Head of Buyout
|
Head of Buyout | Total investments: 0 | Find email | |
|
Angelo J.Y. Koo
Chairman and CEO
|
Chairman and CEO | Total investments: 0 | Find email | |
|
Grant Lin
Senior Vice President
|
Senior Vice President | Total investments: 0 | Find email | |
|
Hamilton Tang
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Lionel de Saint Exupery
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Shengya Bio
|
ShengYa Bio is a biotechnology company that specializes in the research, development, and manufacturing of in vitro diagnostic reagents and equipment. | Series B / Dec 08, 2025 | |
| Redcliff is a drone management company that organizes aerial shows and events for private and public organizations. | Series B / Apr 07, 2025 | ||
| QT Medical’s technology empowers the patients to take an active role in managing their heart disease. Heart disease is responsible for 1 out of every 4 deaths in the U.S. and is the number 1 killer world-wide. No longer do patients with heart disease have to make long trips to their cardiologists, hospitals, or emergency rooms to get diagnostic,hospital-grade ECG scans. They can now perform these tests from the comfort of their homes or anywhere with an internet connection, allowing peace of mind, saving time, reducing stress, and improving outcomes. | $12M / Series B / Sep 26, 2023 | ||
| Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing. | $14.2M / Series C / Aug 25, 2023 | ||
| Ansong Technology is a national high-tech enterprise specializing in the research, development, and sales of high-end bioceramics. | $13.6M / Series C / Aug 25, 2023 | ||
| Micronbrane Medical offers biotechnology services. That provides detect Pathogen Directly from whole blood within a limited time. Sample processing library prep sequencing, data analysing and reporting services. | $4.5M / Series A / Sep 28, 2022 | ||
| Aidoc is an Israel-based startup providing artificial intelligence tools for radiologists. Their products help detect and pinpoint critical anomalies for radiologists through deep learning and AI algorithms that analyze medical images and patient data. Aidoc eases up the work list and frees up time and attention to what matters. The startupdeidentifies these and sends them onto Aidoc’s cloud, where algorithms identify and highlight abnormalities before returning the images to radiology workstations for reidentification.Aidoc's s solutions aid radiologists in reducing turnaround time and increasing quality and efficiency by flagging acute anomalies in real-time. It also offers tests for intracranial hemorrhages and spinal fractures, plus several chest exams for pulmonary embolisms, pneumothorax, rib fractures, and lung nodules.Aidoc was founded by Guy Reiner, Elad Walach, and Michael Braginsky in 2016 and is headquartered in Tel Aviv, Israel. | $110M / Series D / Jun 16, 2022 | ||
| AmazingTalker is an one-on-one learning with native teachers gives students a more personalized learning experience. | $15.5M / Series A / Feb 16, 2022 | ||
| InstaDeep is an EMEA leader in decision-making AI products for the Enterprise, with headquarters in London, and offices in Paris, Tunis, Lagos, Dubai and Cape Town. With expertise in both machine intelligence research and concrete business deployments, the Company provides a competitive advantage to its partners in an AI-first world. Leveraging itsextensive knowhow in GPU-accelerated computing, deep learning and reinforcement learning, InstaDeep has built products, such as its novel DeepChain™ platform, that tackle the most complex challenges across a range of industries. InstaDeep has also developed collaborations with global leaders in the Artificial Intelligence ecosystem, such as Google DeepMind, NVIDIA and Intel. The Company is part of Intel’s AI Builders program and was named an Elite Preferred Deep Learning Partner by NVIDIA | $100M / Series B / Jan 25, 2022 | ||
| Our vision is to empower people to delight their lives how they want when they want it. Our mission is to enable people to be spontaneous through an enjoyable, easy, and reliable booking experience. We are the best way for urbanites to book fun on the spur of the moment. | $15M / Series B / Nov 08, 2021 | ||
| See all 49 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does CDIB Capital invest in?
CDIB Capital invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Series B and Series A stage. Most of the 49 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is CDIB Capital's check size?
CDIB Capital typically joins rounds of $1.5M–$18M at Series A, $6M–$100M at Series B and $4.3M–$40M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CDIB Capital participates in.
How do I contact CDIB Capital?
Public channels for CDIB Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CDIB Capital?
The team at CDIB Capital includes Alex Ying (Head of Buyout), Angelo J.Y. Koo (Chairman and CEO) and Grant Lin (Senior Vice President), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
